The Molecule Is Promising. Can It Survive the Factory?

JOINN Biologics US sells a deceptively practical service: finding out early whether a brilliant biologic can be made, measured and supplied. Its Richmond team now applies that logic from antibody screening to a 2026 biosimilar partnership.